The European Medicines Agency’s safety committee concluded in May 2019 that sexual dysfunction linked to SSRIs and SNRIs, the most widely prescribed classes of antidepressant, can be “long-lasting” and that symptoms “have continued despite discontinuation,” and required member states to update product labelling accordingly within two months. The UK’s product information was updated in line with that EU-wide action the same year. That was a label-level change to the formal prescribing information rather than a UK-originated review, and patient information leaflets, the shorter documents patients actually receive with a prescription, have reportedly still been under separate review by a UK expert working group as recently as 2025.
Health Canada published its own safety review in January 2021, concluding it could neither confirm nor rule out a causal link but committing regulators to work with manufacturers on updated warning language. Australia’s Therapeutic Goods Administration took similar action considerably later, updating product information for all SSRIs and SNRIs in May 2024 to state that sexual dysfunction “can persist for weeks to years” after stopping treatment. Malaysia’s National Pharmaceutical Regulatory Agency issued a comparable safety alert in 2025. Ireland’s Health Products Regulatory Authority and Hong Kong’s Department of Health have both been reported, by patient advocacy groups tracking this issue, to have acted in this space as well, though a primary regulatory document with an exact date for either was not independently locatable at the time of writing; that’s a real gap in the sourcing available to the public, not a reason to doubt the underlying claim, which is corroborated across multiple advocacy and clinical trackers even where the paperwork itself is hard to pin down.
Put together, this means the “seven regulators since 2019” framing describes a six-year drift, not one coordinated moment: the EU acted first, in 2019, and the rest followed unevenly over the following six years, with Australia and Malaysia only catching up in the last two.
Where the US stands
The Food and Drug Administration has not added equivalent language to US antidepressant labelling. A citizen petition requesting such a warning was filed in 2018 by researcher Antonei Csoka and colleagues; the FDA has neither granted nor formally denied it. Frustration with that inaction led the advocacy group Public Citizen to sue the FDA in May 2024 over the delay. A federal court dismissed that suit in March 2025 on procedural standing grounds — a ruling about who could bring the case, not about the underlying medical question. That means there is currently no court-ordered deadline pushing the FDA toward a decision either way.
What this condition actually is, and isn’t
Sexual side effects while actually taking an SSRI or SNRI are common and well established; estimates in the clinical literature range widely, often cited somewhere between a third and most patients depending on the specific drug, dose and how the question is asked, and this on-drug effect isn’t what the recent regulatory actions are about. What’s newer, and what these label changes specifically address, is the smaller but harder-to-dismiss subset of cases where those effects don’t resolve after the person stops taking the medication, sometimes persisting for months or years afterward. The condition at the centre of these warnings is generally referred to as post-SSRI sexual dysfunction, sometimes abbreviated PSSD, referring to sexual side effects, reduced sensation, low libido, difficulty with arousal or orgasm, that in some patients persist after the medication has been fully discontinued rather than resolving with it. Research on how common this is remains limited; a 2024 review in Epidemiology and Psychiatric Sciences specifically flagged the difficulty of establishing reliable incidence and prevalence figures, given inconsistent reporting, diagnostic ambiguity and the challenge of separating drug effects from the depression or anxiety symptoms the medication was prescribed to treat in the first place.
Part of why establishing hard numbers has been slow is that there’s no diagnostic test or biomarker for PSSD; it’s identified by timeline and symptom pattern rather than a scan or blood test, which makes both individual diagnosis and population-level prevalence estimates harder to pin down than for a condition with an objective marker. That difficulty explains why regulators have moved cautiously and unevenly. It doesn’t explain away the reports driving these label changes.
This isn’t an argument against antidepressant treatment, which remains, for many people, an effective and sometimes essential part of managing serious depression and anxiety. It’s also not evidence that everyone who takes an SSRI or SNRI will experience lasting sexual side effects; the available research suggests this is an uncommon outcome, not a typical one, even as regulators increasingly agree it’s a real one.
The seven-country pattern shows something narrower and more procedural: several regulatory bodies have concluded the evidence clears the bar for a label warning; the US regulator, facing a formal request to do the same since 2018, has not yet reached that conclusion either way. Whether that reflects a genuinely higher evidentiary bar at the FDA, institutional caution about a request that arrived as a citizen petition rather than through a pharmaceutical company’s own safety monitoring, or simply a slower-moving process, isn’t something the public record settles. What is on the record is the gap itself, and how long it’s now been open.
Anyone experiencing side effects from a prescribed medication, including sexual side effects that persist after stopping it, should discuss that directly with the prescribing doctor rather than stopping or adjusting treatment independently based on an article like this one.
Note: We are writers, not clinicians, and nothing here is advice about starting, continuing or stopping any medication; anyone with concerns about a prescription should raise them with the prescriber who’s actually treating them.